title: Villoglandular papillary adenocarcinoma of the cervix: a series of 28 cases including two with lymph node metastasis.
abstract: OBJECTIVE
  To investigate the clinicopathologic features, the management, and the outcome of villoglandular papillary adenocarcinoma (VGPA) of the uterine cervix.
  
  
  METHODS
  A retrospective review of patients' clinical characteristics, pathology, and the disease management, together with outcome information.
  
  
  RESULTS
  A total of 28 patients with VGPA were treated. The median age of the patients was 38 years with a range of 26 to 65 years. Sixteen of the 21 patients presented with abnormal bleeding, and 5 patients had an abnormal Papanicolaou (Pap) test result. Nineteen patients had International Federation of Gynecology and Obstetrics stage IB disease, and 5 patients had stage IIB disease. Two of 24 patients, where the lymph node status was known, had positive nodes. Twenty patients underwent different types of radical surgery with or without pelvic radiotherapy, and 8 patients received platinum-based chemotherapy and pelvic radiotherapy with no surgery. The follow-up ranged from 5 to 168 months with a median of 35 months. Twenty-one patients are alive with no evidence of recurrent disease, 5 patients have died because of the disease recurrence, and 2 patients were lost to follow-up. The overall and disease-free 5-year survival for these patients was 82% and 75%, respectively.
  
  
  CONCLUSIONS
  This study confirms the excellent prognosis of VGPA overall compared to the common forms of cervical cancer, but the prognosis is related to stage and pathology. A large multicenter prospective study is warranted to determine the most appropriate treatment for the disease. Until then, a meta-analysis on the subject would be of benefit.
authors.affiliation: Department of Obstetrics and Gynecology, Jordan University of Science and Technology, Irbid, Jordan. isam_l@yahoo.com
authors.forename: Isam M
authors.initials: IM
authors.lastname: Lataifeh
authors.forename: Maysa
authors.initials: M
authors.lastname: Al-Hussaini
authors.forename: Catherine
authors.initials: C
authors.lastname: Uzan
authors.forename: Imad
authors.initials: I
authors.lastname: Jaradat
authors.forename: Pierre
authors.initials: P
authors.lastname: Duvillard
authors.forename: Philippe
authors.initials: P
authors.lastname: Morice
mesh_terms: D000231:Adenocarcinoma, Papillary / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D000328:Adult; D000368:Aged; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D009367:Neoplasm Staging; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate; D002583:Uterine Cervical Neoplasms / Q000401:mortality* / Q000473:pathology / Q000628:therapy